Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 9, 2011, Pages 2641-2645

  Griffith, David A ^a   Hargrove, Diane M ^a   Maurer, Tristan S ^a   Blum, Charles A ^b   De Lombaert, Stéphane ^b   Inthavongsay, John K ^a   Klade, Lee E ^a   MacK, Christine M ^b   Rose, Colin R ^a   Sanders, Martin J ^a   Carpino, Philip A ^a  

^a PFIZER INC   (United States)

^b NEUROGEN CORPORATION   (United States)

Author keywords

NPY Y1R; Obesity; Pyrazolo 1,5 a pyrimidine

Indexed keywords

CP 671906; GLYCOPROTEIN P; N (2 AMINOETHYL) 3 MESITYL 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDIN 7 AMINE; NEUROPEPTIDE Y1 RECEPTOR; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; BINDING AFFINITY; BLOOD PRESSURE; CONFERENCE PAPER; DRUG SYNTHESIS; FEEDING BEHAVIOR; FOOD INTAKE; MOUSE; NONHUMAN; PLASMA CLEARANCE; RAT; REFEEDING; STRUCTURE ACTIVITY RELATION;

ANIMALS; APPETITE DEPRESSANTS; BLOOD PRESSURE; DRUG DISCOVERY; EATING; HUMANS; MICE; MOLECULAR STRUCTURE; PYRAZOLES; PYRAZOLONES; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROPEPTIDE Y;

RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 79955473502     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.116     Document Type: Conference Paper

References (37)

1. A.H. Mikdad , J.S. Marks , D.F. Stroup , and J.L. Gerberding J. Am. Med. Assoc. 291 2004 1238
2. M.L. Isidro , and F. Cordido Mini-Rev. Med. Chem. 9 2009 664
3. D.C. Klonoff , and F.J. Greenway Diabetes Sci. Technol. 2 2008 913
4. M.M. Kamiji , and A. Inui Endocr. Rev. 28 2007 664
5. A. Thorsell , and M. Heilig Neuropeptides 36 2002 182
6. B.G. Stanley , S.E. Kyrkouli , S. Lampert , and S.F. Leibowitz Peptides 7 1986 1986
7. H.A. Wieland , B.S. Hamilton , B. Krist , and H.N. Doods Expert Opin. Invest. Drugs 9 2000 1327
8. A.G. Blomqvist , and H. Herzog Trends Neurosci. 20 1997 294
9. S.O. Fetissov , J. Kopp , and T. Hokfelt Neuropeptides 38 2004 175
10. N. Erondu , T. Wadden , I. Gantz , B. Musser , A.M. Nguyen , H. Bays , G. Bray , P.M. O'Neil , A. Basdevant , K.D. Kaufman , S.B. Heymsfield , and J.M. Amatruda Obesity 15 2007 895
11. Okuno, T.; Takenaka, H.; Aoyama, Y.; Kanda, Y.; Yoshida, Y.; Okada, T.; Hashizume, H.; Sakagami, M.; Nakatani, T.; Hattori, K.; Ichihashi, T.; Yoshikawa, T.; Yukioka, H.; Hanasaki, K.; Kawanishi, Y. Abstract of Papers, 240th National Meeting of the American Chemical Society, Boston, MA, 2010; Abstract MEDI-284.
12. Z.-Y. Sun , Z. Zhu , Y. Ye , B. McKittrick , M. Czarniecki , W. Greenlee , D. Mullins , and M. Guzzi Bioorg. Med. Chem. Lett. 19 2009 6801
13. K. Cho , M. Ando , K. Kobayashi , H. Miyazoe , T. Tsujino , S. Ito , T. Suzuki , T. Tanaka , S. Tokita , and N. Sato Bioorg. Med. Chem. Lett. 19 2009 4781
14. M. Kameda , K. Kobayashi , H. Ito , H. Miyazoe , T. Tsujino , C. Nakama , H. Kawamoto , M. Ando , S. Ito , T. Suzuki , T. Kanno , T. Tanaka , Y. Tahara , T. Tani , S. Tanaka , S. Tokita , and N. Sato Bioorg. Med. Chem. Lett. 19 2009 4325
15. J. Lee , K.-S. Song , J. Kang , S.H. Lee , and J. Lee Curr. Top. Med. Chem. 9 2009 564
16. D.J. MacNeil Curr. Top. Med. Chem. 7 2007 1721
17. Compound 1 was synthesized by the methods described in WO199951600 and the binding affinity against the CRH receptor was measured according to the assays described therein.
18. ElogD was calculated from a model built according to the methods described in Ref. 15b, based on Cubist [Rulequest Research, www.rulequest.com ]. The training set for the model was 33,000 ElogD values measured using methodology described in Ref. 15c.
19. H. Gao , L. Yao , H.W. Mathieu , Y. Zhang , T.S. Maurer , M.D. Troutman , D.O. Scott , R.B. Ruggeri , and J. Lin Drug Metab. Dispos. 36 2008 2130
20. F. Lombardo , M.Y. Shalaeva , K.A. Tupper , and F. Gao J. Med. Chem. 44 2001 2490
21. 1H NMR, MS).
22. For details of this assay, see WO 2001023387.
23. 50 concentration of NPY (range 0.5-1.5 nM), which was determined just prior to each experiment.
24. SD rats, fasted overnight, were anesthetized with inactin (100 mg/kg ip), surgically prepared with tracheal (PE205) and femoral arterial and venous cannula (PE50) and placed on a water-jacketed heating pad. The arterial pressure and heart rate signals were fed into a PONEMAH Physiology Platform (Gould Instrument Systems, Valley View OH) and data were recorded every 5 seconds during the experiment. NPY (5 μg in 0.25 mL of saline), was administered to the rats at 15 min intervals as an iv bolus. Following the third bolus injection of NPY, the test compound (3 mg/kg in a saline vehicle, 1 mL/kg) was dosed iv and three subsequent NPY injections were administered.
25. T.T. Wager , R.Y. Chandrasekaran , X. Hou , M.D. Troutman , P.R. Verhoest , A. Villalobos , and Y. Will ACS Chem. Neurosci. 2010 1
26. Selectivity assays (42 receptors, ion channels and enzymes) were performed by MDS Pharma (Taipei, Taiwan).
27. CRH receptor binding activity was measured at Cerep (France); www.cerep.fr .
28. For the determination of pharmacokinetic parameters, jugular vein cannulated SD rats were dosed with 2f by oral gavage (3 mg/kg in 0.5% methyl cellulose at 2 mL/kg, n = 2) or via the jugular vein (1.0 mg/kg in 50% PEG vehicle at 1 ml/kg, n = 2). Prior to dosing, rats were fasted overnight with water available ad libitum.
29. B/P ratios were calculated from unbound plasma - to - brain fraction ratios; equilibrium dialysis was used to measure unbound fraction of compound in brain homogenates and whole plasma from rats and mice.
30. J.C. Kalvass , and T.S. Maurer Biopharm. Drug Dispos. 23 2002 327
31. A.H. Schinkel Adv. Drug Delivery Rev. 36 1999
32. M. Morgenthaler , E. Schweizer , A. Hoffmann-Roder , F. Benini , R.E. Martin , G. Jaeschke , B. Wagner , H. Fischer , S. Bendels , D. Zimmerli , J. Schneider , F. Diederich , M. Kansy , and K. Muller ChemMedChem 2 2007 1100
33. All animal protocols were reviewed and approved by the Pfizer or Neurogen Institutional Animal Care and Use Committees.
34. SD rats with icv cannula were fed powdered rat chow ad libitum. Between 10-11 am during the light cycle, 2f (120 μg) or vehicle (1 μL of propylene glycol) were co-infused with NPY (5 μg in 4 μL sterile water) via the icv cannula (total volume 5 μL over 1 min). After dosing, food intake over the next 4 h was measured. Rats received two treatments in a cross-over experiment separated by 2 days.
35. SD rats were individually housed in suspended wire cages with powdered chow and water provided ad libitum. Before the experiment, rats were fasted overnight. On the day of the experiment, rats were dosed with 2f (40 mg/kg, po) or vehicle (0.5% methyl cellulose in water, dosing volume 1.5 mL). Food, in pre-weighed jars, was restored to the cages 2 or 4 h post dose. Food intake was recorded 2 and 4 h after restoring food.
36. Wistar rats that had been acclimated to a continuous food intake monitoring system (Columbus Instruments, Columbus OH) were dosed with 2f (40 mg/kg, po) or vehicle, 30 min prior to the dark cycle. The system recorded food intake every 10 min for 18 h post-dose.
37. CSF samples were obtained 2 h post dose (n = 2). Rats were anesthetized with metofane. CSF was drawn directly from the cisterna magna through a 26-gauge needle.